Prognostic value of hyperuricemia in patients with acute coronary syndrome: A meta-analysis
Cuifang He1, Peihuan Lin1, Wenbing Liu1
1Department of CCU, The No.6 People's Hospital, Huizhou, China.
Insights
Elevated uric acid levels, or hyperuricemia, independently predict major adverse cardiovascular events and death in acute coronary syndrome (ACS) patients. This finding can improve risk stratification for ACS outcomes.
Area of Science:
- Cardiology
- Clinical Biochemistry
Background:
- The prognostic value of elevated uric acid in acute coronary syndrome (ACS) patients remains debated.
- Hyperuricemia is a common finding in patients with cardiovascular disease.
Purpose of the Study:
- To evaluate the prognostic significance of hyperuricemia in patients diagnosed with acute coronary syndrome (ACS).
- To assess the association between high uric acid levels and adverse cardiovascular outcomes in ACS patients.
Main Methods:
- A systematic literature search was conducted across multiple databases (PubMed, Embase, VIP, CNKI, WanFang) up to June 2018.
- Included observational studies investigating hyperuricemia and its association with major adverse cardiovascular events (MACEs), all-cause mortality, or cardiovascular mortality in ACS patients.
Main Results:
- Nine studies involving 8776 ACS patients were analyzed.
- Hyperuricemia was associated with a significantly increased risk of MACEs (RR: 1.86), all-cause mortality (RR: 1.86), and cardiovascular mortality (RR: 1.74) after adjusting for conventional risk factors.
- Stratified analyses confirmed the consistent prognostic significance of hyperuricemia across subgroups.
Conclusions:
- Hyperuricemia serves as an independent predictor of adverse outcomes, including MACEs and mortality, in ACS patients.
- Measuring uric acid levels holds potential for enhancing the risk stratification of ACS patients.
Background:
The prognostic significance of elevated circulating uric acid level in patients with acute coronary syndrome (ACS) is conflicting. This meta-analysis aimed to assess the prognostic value of hyperuricemia in patients with ACS.
Methods:
A comprehensive literature search was performed in Pubmed, Embase, VIP, CNKI and WanFang databases up to 16 June 2018. All observational studies that investigated the prognostic value of hyperuricemia in ACS patients were selected. Outcome of interests was major adverse cardiovascular events (MACEs), all-cause mortality or cardiovascular mortality.
Results:
A total of nine studies enrolling 8776 ACS patients were included and analysed. ACS patients with hyperuricemia had an increased risk of MACEs (risk ratio [RR]: 1.86; 95% confidence intervals [CI]: 1.47-2.35), all-cause mortality (RR 1.86; 95% CI: 1.49-2.32) and cardiovascular mortality (RR: 1.74; 95% CI: 1.36-2.22) after adjustment for the conventional risk factors. Stratified analysis showed that the prognostic significance of hyperuricemia was consistently observed in each subgroups.
Conclusions:
This meta-analysis suggests that hyperuricemia independently predicts MACEs and death in ACS patients. Determination of uric acid level has potential to improve risk stratification of adverse outcomes in ACS patients.
More Related Videos
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome V: Nursing Management
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Directing Effect of Substituents: meta-Directing Groups


